RG
SRPT icon

Redmile Group’s Sarepta Therapeutics SRPT Stock Holding History

Redmile Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-231,595
Closed -$31.9M – 78
2023
Q1 		$31.9M Buy
+231,595
New +$30M 1.39% 25
2019
Q3 		– Sell
-412,000
Closed -$62.6M – 81
2019
Q2 		$62.6M Buy
+412,000
New +$50.1M 1.77% 19
2018
Q3 		– Sell
-31,100
Closed -$4.11M – 93
2018
Q2 		$4.11M Buy
+31,100
New +$2.93M 0.14% 62
2016
Q4 		– Sell
-640,400
Closed -$39.3M – 58
2016
Q3 		$39.3M Buy
+640,400
New +$19.4M 3.13% 13

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group's SRPT Position: Q2 2023 in Review

Redmile Group sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 231,595 shares — an estimated $31.9M sold.

Redmile Group first reported a position in SRPT in Q3 2016 and held it in 4 quarters. The position peaked at $62.6M in Q2 2019. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

  • Redmile Group reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Redmile Group sold 231,595 Sarepta Therapeutics shares in Q2 2023, an estimated $31.9M.
  • Redmile Group first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 4 quarters.
  • Redmile Group's Sarepta Therapeutics position peaked at $62.6M in Q2 2019.
  • 404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Redmile Group's 13F filing for Q2 2023, filed 14 Aug 2023.